Figitumumab development discontinued for non-adenocarcinoma NSCLC
Adding the novel insulin-like growth factor 1 receptor (IGF-1R) inhibitor figitumumab to the epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung ...
News-Medical.net - Fri, 12 Dec 2014 14:14

Research and Markets: Lung Adenocarcinoma - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration ...
Business Wire (press release) - Mon, 01 Dec 2014 01:11



Vargatef® (nintedanib*) approved in the EU for lung cancer patients with ...
Nintedanib*, when added to docetaxel, demonstrated over one year (12.6 months) median overall survival for advanced lung cancer patients with adenocarcinoma after first-line chemotherapy (vs. 10.3 months for patients receiving docetaxel alone)1.
PipelineReview.com (press release) - Thu, 27 Nov 2014 00:03

Boehringer's Vargatef gains approval in EU for lung cancer
The Pharma Letter - Fri, 28 Nov 2014 04:33

Vargatef cleared in Europe for lung cancer
Seeking Alpha - Fri, 28 Nov 2014 06:15

Boehringer gets EU marketing approval for lung cancer drug Vargatef
Pharmaceutical Business Review - Thu, 27 Nov 2014 23:21

Effects of simvastatin on cell viability and proinflammatory pathways in lung ...
... human lung adenocarcinoma cell line GLC-82, the effects of a 24-hour treatment with simvastatin on hydrogen peroxide (H2O2)-induced changes in cell viability, ERK phosphorylation, matrix metalloproteinase (MMP) expression, innate immunity signaling ...
7thSpace Interactive (press release) - Fri, 28 Nov 2014 17:41

Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes ...
Sarcoid-like reaction is often seen in various types of carcinoma, not only in the primary tumor, but also in regional lymph nodes, and can occur at any time, not only at the time of diagnosis, but also after treatment. However, few cases of ...
7thSpace Interactive (press release) - Sat, 13 Dec 2014 02:52



Adenocarcinoma polmone g2 stadio 1, chemioterapia sempre necessaria?
“Mio padre dell' età di 73 anni è stato sottoposto ad una loboctomia per asportare un adenocarcinoma al polmone g2 al 1 stadio ,i linfonodi erano esenti di neoplasia e non c 'erano metastasi . I dott. del Regina Elena dove è stato operato hanno detto ...
MedicinaLive - Wed, 17 Dec 2014 23:52



Adenocarcinoma polmonare Dalle Ue via libera a un nuovo farmaco
Il farmaco, in associazione a docetaxel, è indicato per il trattamento di pazienti adulti con carcinoma polmonare non a piccole cellule (NSCLC), localmente avanzato, metastatico o localmente ricorrente con istologia adenocarcinoma, dopo chemioterapia ...
L'Eco di Bergamo - Mon, 01 Dec 2014 11:18

Targeted next-generation sequencing reveals a high number of genomic ...
"Our data did not identify any specific mutation as a single driver gene, as found in adenocarcinoma of the lung, however our data suggests that in MPM there is an accumulation of several non-driver mutations, which may explain the extremely long ...
Medical Xpress - Wed, 17 Dec 2014 13:56


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014